10x Genomics Is Maintained at Overweight by Barclays
10x Genomics Analyst Ratings
Barclays Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $19
Morgan Stanley Maintains 10x Genomics(TXG.US) With Buy Rating, Maintains Target Price $30
A Quick Look at Today's Ratings for 10x Genomics(TXG.US), With a Forecast Between $14 to $30
10x Genomics Is Maintained at Neutral by JP Morgan
10x Genomics Analyst Ratings
UBS Maintains Neutral on 10x Genomics, Lowers Price Target to $20
A Quick Look at Today's Ratings for 10x Genomics(TXG.US), With a Forecast Between $18 to $25
Strategic Pricing and Market Expansion Drive 10x Genomics Buy Rating
Leerink Partners Maintains 10x Genomics(TXG.US) With Buy Rating
TD Cowen Maintains 10x Genomics(TXG.US) With Hold Rating, Cuts Target Price to $18
TD Cowen Reaffirms Their Hold Rating on 10x Genomics (TXG)
Barclays Maintains 10x Genomics(TXG.US) With Buy Rating, Maintains Target Price $21
10x Genomics Is Maintained at Overweight by Barclays
10x Genomics Analyst Ratings
Barclays Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $21
Temporary Disruption at 10x Genomics: A Buy Rating Amidst Sales Force Realignment and Strong Product Fundamentals
Stifel Maintains 10x Genomics(TXG.US) With Buy Rating, Maintains Target Price $25
10x Genomics Price Target Maintained With a $30.00/Share by Stephens & Co.